UBS lowered the firm’s price target on Avadel Pharmaceuticals (AVDL) to $14 from $22 and keeps a Buy rating on the shares following the preliminary Q4 report. Lumryz’s growth path is intact and the stock’s risk/reward is “compelling” after the recent weakness, the analyst tells investors in a research note. UBS lowered its Lumryz fiscal 2025 and beyond sales estimates, driven by slower ramp of patients capture and higher discontinuation. However, it still believes that at the current valuation, the stock is “significantly cheap and can recover” in the second half of 2025 as Lumryz growth starts to come back.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Venu Sports JV discontinued, Walgreens reports Q1 beat: Morning Buzz
- Oppenheimer cuts Avadel target, would buy on weakness
- Avadel Pharmaceuticals price target lowered to $17 from $23 at Craig-Hallum
- Piper Sandler cuts Avadel Pharmaceuticals price target, says staying bullish
- Avadel Pharmaceuticals price target lowered to $21 from $25 at H.C. Wainwright